PCSK9 and diabetes mellitus: In summary, our cross-sectional analysis demonstrates important disparities in lipid control, as well as in the use of statins, ezetimibe, PCSK9 inhibitors, and icosapent ethyl in US adults with DM across sociodemographic and DM risk groups.